[1] |
JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui.
Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
|
[2] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[3] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[4] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[5] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[6] |
ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun.
Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.
|
[7] |
LIU Qian, HU Jing, LI Bo, YANG Xiaojing.
Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
|
[8] |
YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo.
Risks of safety Qingkailing oral preparation
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
|
[9] |
ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling.
Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
|
[10] |
ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan.
Medications of apatinib mesylate in patients with malignant tumors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
|
[11] |
CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan.
One case of abnormal uterine bleeding caused by Baofukang suppository
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
|
[12] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B6 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
|
[13] |
ZHANG Lei, LYU Jian, XIE Yanming.
Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806.
|
[14] |
LIU Jingjing, DAI Zhong, YANG Jianbo, WANG Ying, XU Beilei, LIU Yue, WANG Qi, MA Shuangcheng.
Spectrum-fect relationship of Ginseng Radix et Rhizoma Rubra and Polygonum Multiflorum Radix Preparata medicinal pair in protection of nerve cells
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 623-628.
|
[15] |
CHEN Xiao, GUO Xiaojing, XU Jinfang, WEI Lianhui, CHEN Chenxin, LIANG Jizhou, ZHENG Yi, YE Xiaofei.
Machine learning method in the detection of adverse drug reaction signals of brigatinib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 639-645.
|